A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
Corey J. Langer(University of Pennsylvania), M. S. Berger(Duke University), A Somfay, Judy Schnyder(Gem Pharmaceuticals (United States)), P Kovács, Gábor Pajkos, A. Szczęsna, L. Johnetta Blakely, Petr Zatloukal(Heidelberg University), István Albert(Alleanza Contro il Cancro), Andrzej Każarnowicz, M. Moezi, Petar Petrov(Agennix (United States)), Marshall T. Schreeder(Clearview Cancer Institute)
Cited by 19
Related Papers
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
|Annals of Oncology|2010|644
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|454